Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.

Nature Communications
Yu-Chen WangLili Yang

Abstract

Targeting tumor-associated macrophages (TAMs) is a promising strategy to modify the immunosuppressive tumor microenvironment and improve cancer immunotherapy. Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain; small molecule MAO inhibitors (MAOIs) are clinically used for treating neurological disorders. Here we observe MAO-A induction in mouse and human TAMs. MAO-A-deficient mice exhibit decreased TAM immunosuppressive functions corresponding with enhanced antitumor immunity. MAOI treatment induces TAM reprogramming and suppresses tumor growth in preclinical mouse syngeneic and human xenograft tumor models. Combining MAOI and anti-PD-1 treatments results in synergistic tumor suppression. Clinical data correlation studies associate high intratumoral MAOA expression with poor patient survival in a broad range of cancers. We further demonstrate that MAO-A promotes TAM immunosuppressive polarization via upregulating oxidative stress. Together, these data identify MAO-A as a critical regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunotherapy.

References

Mar 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maïa ChanrionJean-Marie Darbon
Jul 26, 2008·Advanced Drug Delivery Reviews·Marco BortolatoJean C Shih
Nov 29, 2008·The New England Journal of Medicine·G LenzUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Feb 7, 2009·Nature Reviews. Immunology·Dmitry I Gabrilovich, Srinivas Nagaraj
Sep 22, 2010·Nature Immunology·Subhra K Biswas, Alberto Mantovani
Dec 15, 2010·Cleveland Clinic Journal of Medicine·Molly WimbiscusDonald Malone
Aug 13, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marco BortolatoJean C Shih
Nov 24, 2011·Experimental Neurobiology·Peter Riederer, Gerd Laux
Apr 17, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Soo Jung ParkIlo Jou
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Oct 3, 2012·PloS One·Marc BeyerJoachim L Schultze
Jan 10, 2013·Annual Review of Immunology·Steven J Van Dyken, Richard M Locksley
Apr 27, 2013·Nature·Thomas A WynnJeffrey W Pollard
Nov 21, 2013·Journal of Parkinson's Disease·Vera DiasM Maral Mouradian
May 29, 2014·The Journal of Clinical Investigation·Jason Boyang WuLeland W K Chung
Jul 19, 2014·Immunity·Roy Noy, Jeffrey W Pollard
Aug 19, 2014·Nature Reviews. Drug Discovery·Katrina J Falkenberg, Ricky W Johnstone
Oct 29, 2014·Molecular Psychiatry·J TiihonenT Paunio
Jan 22, 2015·Proceedings of the National Academy of Sciences of the United States of America·Drake J SmithLili Yang
Sep 9, 2015·The New England Journal of Medicine·Antoni Ribas
Nov 26, 2015·Nature Reviews. Immunology·Yonit LavinMiriam Merad
Feb 13, 2016·Oncotarget·Swati KushalJean C Shih
Feb 26, 2016·Annual Review of Immunology·Sébastien TalbotClifford J Woolf
Mar 2, 2016·Annual Review of Immunology·Susanne H BaumeisterArlene H Sharpe
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Jun 14, 2016·Journal of Dermatological Science·Taku FujimuraSetsuya Aiba
Sep 8, 2016·Proceedings of the National Academy of Sciences of the United States of America·Verena SchuetteSven Burgdorf
Nov 1, 2016·Nature·Megan M KanedaJudith A Varner
Nov 3, 2016·Frontiers in Pharmacology·John P M Finberg, Jose M Rabey
Nov 12, 2016·Cell Research·Wei Zheng, Jeffrey W Pollard
Mar 5, 2017·Immunological Reviews·Arlene H Sharpe
Jul 19, 2017·Journal for Immunotherapy of Cancer·Michael A CannarileDominik Rüttinger
Jul 20, 2017·The Journal of Pathology·Pei Chuan LiJean Chen Shih
Sep 6, 2017·The Journal of Clinical Investigation·Bo LiLili Yang
Oct 11, 2017·Nature Reviews. Immunology·Arlene H Sharpe, Kristen E Pauken
Oct 21, 2017·Brain : a Journal of Neurology·Junchao TongStephen J Kish

❮ Previous
Next ❯

Software Mentioned

Tumor Immune Dysfunction and Exclusion ( TIDE )
R package
scRNASeq
TIDE
FlowJo
Seurat
UMAP
GraphPad Prism
Cellranger Software Suite
cellranger

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.